Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Blood (2023) 142 (Supplement 1): 624.

https://doi.org/10.1182/blood-2023-179291

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Primary Myelofibrosis in Japan: A Nationwide Survey over a 17-Year Study Period

Katsuto Takenaka, MD PhD, Kazuya Shimoda, MD, PhD, Naoyuki Uchida, MDPhD, Taizo Shimomura, MD PhD, Koji Nagafuji, MD PhD, Tadakazu Kondo, MD PhD, Hirohiko Shibayama, MDPhD, Takehiko Mori, MD PhD, Kensuke Usuki, MD PhD, Taichi Azuma, MDPhD, Yutaka Tsutsumi, MD PhD, Junji Tanaka, MD PhD, Hitomi Dairaku, Keitaro Matsuo, MDPhD, Keiya Ozawa, MD PhD, Mineo Kurokawa, MD, PhD, Shunya Arai, MD, PhD, Koichi Akashi, MD PhD

Blood (2016) 128 (22): 3126.

https://doi.org/10.1182/blood.V128.22.3126.3126

Published: 2016

Journal Articles

IDH1 and IDH2 Mutations Confer An Adverse Effect In Patients With Acute Myeloid Leukemia Lacking The NPM1 Mutation

Shunichiro Yamaguchi, MD, Eisaku Iwanaga, MD, PhD, Kenji Tokunaga, MD, Tomoko Nanri, MD, PhD, Taizo Shimomura, MD, PhD, Hitoshi Suzushima, MD, PhD, Yutaka Okuno, MD, PhD, Hiroaki Mitsuya, MD, PhD, Norio Asou, MD, PhD

Blood (2013) 122 (21): 4977.

https://doi.org/10.1182/blood.V122.21.4977.4977

Published: 2013

Journal Articles

Accumulation Of Gene Alterations Of TP53 , Crebbp and IKZF1 Is a Prognostic Factor In Adult Acute Lymphoblastic Leukemia

Kenji Tokunaga, MD, Shunichro Yamaguchi, MD, Taizo Shimomura, MD, PhD, Hitoshi Suzushima, MD, PhD, Yutaka Okuno, MD, PhD, Hiroaki Mitsuya, MD, PhD, Norio Asou, MD, PhD

Blood (2013) 122 (21): 1386.

https://doi.org/10.1182/blood.V122.21.1386.1386

Published: 2013

Journal Articles

Crebbp HAT Domain Mutations Are Frequently Detected in Adult Acute Lymphoblastic Leukemia

Kenji Tokunaga, MD, Shunichiro Yamaguchi, MD, Eisaku Iwanaga, MD, PhD, Tomoko Nanri, MD, PhD, Taizo Shimomura, MD, PhD, Hitoshi Suzushima, MD, PhD, Mitsuya Hiroaki, MD, PhD, Norio Asou, MD, PhD

Blood (2012) 120 (21): 1419.

https://doi.org/10.1182/blood.V120.21.1419.1419

Published: 2012

Journal Articles

Prognostic Impact and Concurrent Genetic Alterations of CEBPA Double Mutations in Adults with Cytogenetically Intermediate-Risk Acute Myeloid Leukemia.

Shunichiro Yamaguchi, MD, Kenji Tokunaga, MD, Eisaku Iwanaga, MD, PhD, Tomoko Nanri, MD, PhD, Taizo Shimomura, MD, PhD, Hitoshi Suzushima, MD, PhD, Hiroaki Mitsuya, Norio Asou, MD, PhD

Blood (2012) 120 (21): 2538.

https://doi.org/10.1182/blood.V120.21.2538.2538

Published: 2012

Journal Articles

IDH2 Mutations Have An Unfavorable Impact in Elderly Patients with Acute Myeloid Leukemia

Shunichro Yamaguchi, MD, Eisaku Iwanaga, MD, Kenji Tokunaga, MD, Tomoko Nanri, MD, PhD, Hitoshi Suzushima, MD, PhD, Taizo Shimomura, MD, PhD, Hiroaki Mitsuya, MD, PhD, Norio Asou, MD, PhD

Blood (2011) 118 (21): 2519.

https://doi.org/10.1182/blood.V118.21.2519.2519

Published: 2011

Journal Articles

Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System

Tetsuzo Tauchi, M.D., Masahiro Kizaki, M.D., Shinichiro Okamoto, M.D., Hideo Tanaka, M.D., Mitsune Tanimoto, M.D., Koiti Inokuchi, M.D., Tohru Murayama, M.D., Yoshio Saburi, M.D., Masayuki Hino, M.D., Mitsuru Tsudo, M.D., Taizo Shimomura, M.D., Yasushi Isobe, M.D., Kazuo Oshimi, MD, Kazuo Dan, M.D., Kazuma Ohyashiki, M.D., Yasuo Ikeda, M.D.

Blood (2010) 116 (21): 2287.

https://doi.org/10.1182/blood.V116.21.2287.2287

Published: 2010

Journal Articles

Activated Dendritic Cells From Bone Marrow Cells of Mice Receiving Cytokine-Expressing Tumor Cells Are Associated With the Enhanced Survival of Mice Bearing Syngeneic Tumors

Shin-ichiro Fujii, Hirofumi Hamada, Koji Fujimoto, Taizo Shimomura, Makoto Kawakita

Blood (1999) 93 (12): 4328–4335.

https://doi.org/10.1182/blood.V93.12.4328

Published: 1999

NARROW

Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis

Clinical Outcomes of Patients with Primary Myelofibrosis in Japan: A Nationwide Survey over a 17-Year Study Period

IDH1 and IDH2 Mutations Confer An Adverse Effect In Patients With Acute Myeloid Leukemia Lacking The NPM1 Mutation

Accumulation Of Gene Alterations Of TP53 , Crebbp and IKZF1 Is a Prognostic Factor In Adult Acute Lymphoblastic Leukemia

Crebbp HAT Domain Mutations Are Frequently Detected in Adult Acute Lymphoblastic Leukemia

Prognostic Impact and Concurrent Genetic Alterations of CEBPA Double Mutations in Adults with Cytogenetically Intermediate-Risk Acute Myeloid Leukemia.

IDH2 Mutations Have An Unfavorable Impact in Elderly Patients with Acute Myeloid Leukemia

Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System

Activated Dendritic Cells From Bone Marrow Cells of Mice Receiving Cytokine-Expressing Tumor Cells Are Associated With the Enhanced Survival of Mice Bearing Syngeneic Tumors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only